Pulmatrix PULM 深 沪
已收盘 08-01 16:00:00 美东时间
5.333
-0.297
-5.28%
华盛通- 最 高5.5458
- 今 开5.45
- 成交量 5998股
- 最 低 5.333
- 昨 收 5.63
- 总市值 1947.77万
- 52周最高 10.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.78
- 委 比 -71.53%
- 总股本 365.23万
- 历史最高 4235.00
- 量 比 0.74
- 振 幅 3.78%
- 历史最低 1.55
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive lung disease treatments, announced it will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025. The presentation will be available live and archived on the company’s investor website. Pulmonx develops innovative devices like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System to treat severe emphysema/COPD. The Zeph...
07-29 20:05
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Pulmonx Corporation announced on July 16, 2025, that it will release its second-quarter 2025 financial results after market close on July 30, 2025. A conference call to discuss the results will follow at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Pulmonx investor website. Pulmonx is a global leader in minimally invasive lung disease treatments, offering products like the Zephyr® Endobronchial Valve for emphy...
07-16 20:05
Pulmatrix Stockholders Approve Merger with Cullgen
Pulmatrix ( ($PULM) ) has issued an update. On June 16, 2025, Pulmatrix held a ...
06-17 04:53
Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Pulmonx Corporation will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast will be available on the Pulmonx website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), particularly for patients with severe emphysema. The company's products, including the FDA-approved Zephyr® Endobronch...
05-28 20:05
Pulmatrix GAAP EPS of -$0.50
Pulmatrix press release (NASDAQ:PULM): Q1 GAAP EPS of -$0.50. The Company's total cash and cash equivalents balance as of March 31, 2025, was $7.7 million. The Company anticipates that its cash positi...
05-15 20:24
Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.
05-15 20:21
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberlan...
05-14 04:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 28.9% to ...
03-19 05:05
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the ...
02-20 20:00
美股借壳上市：中国Biotech的新出路？
转自：新康界 2024年12月23日，Inmagene Biopharmaceuticals（下称“创响生物”）宣布与Ikena Oncology(NASDA...
02-10 18:56
